Researchers at the Laboratory of Pharmaceutical Pharmacology (Latvian Institute of Organic Synthesis) have proposed a novel pharmacological approach to increase levels of polyunsaturated fatty acids.
It is well known that long-chain ω-3 polyunsaturated fatty acids (PUFAs) induce cardiometabolic benefits. However, it should be noted that complete oxidation of PUFAs is more than 2 times faster than the oxidation of saturated fatty acids, thus, one can assume that dietary PUFAs are less likely to accumulate to reach the levels/ratios required to induce beneficial effects.
Janis Kuka et.al. has published their research in the journal Oxidative Medicine and Cellular Longevity (IF = 6.543) showing that partial pharmacological inhibition of fatty acid oxidation is a new strategy to selectively
increase levels of PUFAs and modulate lipid handling in order to prevent cardiometabolic disturbances present in metabolic syndrome.
These successful results raise expectations for the successful translation of such a strategy to clinical settings.
Read the article:
Kuka, J.; Makrecka-Kuka, M.; Vilks, K.; Korzh, S.; Cirule, H.; Sevostjanovs, E.; Grinberga, S.; Dambrova, M.; Liepinsh, E.
Inhibition of Fatty Acid Metabolism Increases EPA and DHA Levels and Protects against Myocardial Ischaemia-Reperfusion Injury in Zucker Rats
Oxid. Med. Cell. Longev. 2021, 7493190, doi: 10.1155/2021/7493190